Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
The high growth rate of the prescription hormone drug segment in thepediatric population, both domestic and worldwide, can be attributed to anincrease in the incidence of diabetes, thyroid conditions, and growthdisorders, as well as improved screening procedures, better products,availability, effectiveness, education and delivery techniques suitable forchildren. Within the hormone segment, the highest growth rates are forantidiabetic agents and growth hormone drugs, at 9.1% and 14.4% respectivelyfrom 2004 to 2006 and estimated at 5.4% and 10.8% between 2006 and 2011.
"While the focus of most healthcare watchers has been the aging of theworld population, one must not forget that children number nearly 2.5 billion,or 40% of the humans on the planet," according to Bruce Carlson, publisher ofKalorama Information. "Developers are starting to see that there is a largeunmet need in pediatrics, especially in the hormone category."
Kalorama Information's report The World Market for Pediatric Drugs coversanti-infectives, cancer therapies, and drugs for allergy, respiratory,cardiovascular, central nervous system, gastrointestinal and hormonetreatments. Each segment details products, market estimates, forecasts through2011 and competitive analyses of leading providers. Extensive tables ofproducts in research and development and in-depth discussions of current andfuture issues and trends are also included, with additional insight from morethan 100 interviews with key industry experts. The report can be purchaseddirectly from Kalorama Information by visitinghttp://www.kaloramainformation.com/Pediatric-Drugs-Worldwide-1399511/.
About Kalorama Information
Kalorama Information supplies the latest in independent market research inthe life sciences, as well as a full range of custom research services. Formore information, contact Tom Ehart at 240-747-3014 email@example.com, or visit http://www.KaloramaInformation.com.
SOURCE Kalorama Information
You May Also Like